Allogeneic Transplant and Gene Therapy: Evolving Toward a Cure.

Area of Science:

• Hematology
• Gene Therapy
• Immunology

Background:

• Sickle cell disease (SCD) is a debilitating genetic blood disorder.
• Current curative options for SCD include hematopoietic cell transplant (HCT), gene therapy, and gene editing.
• These advanced therapies face challenges such as graft rejection, graft-versus-host disease (GVHD), and limitations in myeloablative approaches.

Purpose of the Study:

• To review recent advancements in curative therapies for SCD over the past five years.
• To highlight the need for comparative trial data to guide the selection of optimal curative strategies.
• To identify areas for improvement in existing and emerging SCD treatments.

Main Methods:

• Literature review of studies published within the last five years.
• Focus on allogeneic human leukocyte antigen (HLA)-matched sibling and haploidentical HCT, gene therapy, and gene editing.
• Analysis of strategies to mitigate risks associated with HCT and limitations of gene-based therapies.

Main Results:

• Significant progress has been made in HCT, gene therapy, and gene editing for SCD.
• Comparative efficacy and safety data across these modalities remain limited.
• Novel strategies are emerging to address graft rejection and GVHD in haploidentical HCT.
• Myeloablative requirements and long-term effects of gene therapies present ongoing challenges.

Conclusions:

• Hematopoietic cell transplant (HCT), gene therapy, and gene editing represent promising curative avenues for sickle cell disease (SCD).
• The lack of comparative data hinders optimal treatment selection for individual patients.
• Further research and clinical trials are essential to refine these therapies, reduce associated risks, and expand access to curative care for SCD.